A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

NCT01931839 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1164

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

Interventions

DRUG: Lumacaftor Plus Ivacaftor Combination
DRUG: Ivacaftor

Sponsor

Vertex Pharmaceuticals Incorporated